Review
Oncology
Robert Foerster, Daniel Rudolf Zwahlen, Andre Buchali, Hongjian Tang, Christina Schroeder, Paul Windisch, Erwin Vu, Sati Akbaba, Tilman Bostel, Tanja Sprave, Constantinos Zamboglou, Thomas Zilli, Jean-Jacques Stelmes, Tejshri Telkhade, Vedang Murthy
Summary: Stereotactic body radiotherapy (SBRT) is proven effective and well tolerated in low- and intermediate-risk prostate cancer patients. However, its routine application in high-risk patients requires further investigation.
Review
Oncology
Rohann J. M. Correa, Andrew Loblaw
Summary: Stereotactic body radiotherapy (SBRT) shows potential in effectively treating high-risk prostate cancer (HRPC) by using ultra-hypofractionation (UHRT) and advanced imaging and planning techniques to deliver radiotherapy safely and efficiently.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Hideya Yamazaki, Gen Suzuki, Koji Masui, Kei Yamada, Takashi Ueda, Takumi Shiraishi, Atsuko Fujihara, Takashi Kato, Yasutoshi Hashimoto, Haruumi Okabe
Summary: This study compared outcomes of patients with ultra-high iPSA levels to other high-risk patients after radiotherapy. The results showed that patients with ultra-high iPSA levels had worse biochemical disease-free survival and distant metastasis-free survival rates. The ultra-high iPSA group had higher rates of distant metastases, but similar rates of local failure and pelvic lymph node recurrence. Ultra-high iPSA levels could be considered as a candidate factor to identify high-risk patients who require intensified treatment.
Article
Oncology
Yat Man Tsang, Hannah Tharmalingam, Katherine Belessiotis-Richards, Shreya Armstrong, Peter Ostler, Robert Hughes, Roberto Alonzi, Peter J. Hoskin
Summary: This study compared biochemical control rates and toxicities in low-and intermediate risk prostate cancer patients treated with different radiation therapies. The 26 Gy/2 fractions HDR BT provided equivalent biochemical control with lower toxicity compared to 36.25 Gy/5 fractions SABR. Both 2-fraction HDR BT and 5-fraction SABR achieved better biochemical control rates than single dose 19 Gy HDR BT.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Imraan Jan, Rahul R. Parikh
Summary: The Oncology Grand Rounds series aims to help readers understand how to apply academic studies to clinical practice, enhancing their understanding of clinical diagnostic and treatment challenges.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Orla A. Houlihan, Kelly Redmond, Ciaran Fairmichael, Ciara A. Lyons, Conor K. McGarry, Darren Mitchell, Aidan Cole, John O'Connor, Stephen McMahon, Denise Irvine, Wendy Hyland, Michael Hanna, Kevin M. Prise, Alan R. Hounsell, Joe M. O'Sullivan, Suneil Jain
Summary: The feasibility of comparing P-SABR with PPN-SABR in patients with unfavorable intermediate- or high-risk localized prostate cancer was investigated, and potential toxicity biomarkers were explored. The results showed that both P-SABR and PPN-SABR treatments were well-tolerated, and the differences in toxicity between the two treatment groups might be related to quantifiable biomarkers.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Rasmus Lubeck Christiansen, Lars Dysager, Christian Ronn Hansen, Henrik Robenhagen Jensen, Tine Schytte, Christina Junker Nyborg, Anders Smedegaard Bertelsen, Soren Nielsen Agergaard, Faisal Mahmood, Steinbjorn Hansen, Olfred Hansen, Carsten Brink, Uffe Bernchou
Summary: This study investigated the potential benefits of MR-guided online adapted radiotherapy (MRgART) compared to standard radiotherapy for high-risk prostate cancer. The results showed that MRgART resulted in lower doses to critical organs and reduced the risks of urine incontinence, urine voiding pain, and acute gastrointestinal toxicity in comparison to standard radiotherapy.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Urology & Nephrology
Francesco Chierigo, Mike Wenzel, Christoph Wuernschimmel, Rocco Simone Flammia, Benedikt Horlemann, Zhe Tian, Fred Saad, Felix K. H. Chun, Markus Graefen, Michele Gallucci, Shahrokh F. Shariat, Guglielmo Mantica, Marco Borghesi, Nazareno Suardi, Carlo Terrone, Pierre Karakiewicz
Summary: This study compared the survival rates between hormone therapy and hormone therapy plus chemotherapy in high-risk patients. The results showed that hormone therapy had a better cancer-specific survival rate in the overall NCCN high-risk cohort and the JH high-risk and very high-risk subgroup.
JOURNAL OF UROLOGY
(2022)
Article
Oncology
Hima Bindu Musunuru, Patrick Cheung, Danny Vesprini, Stanley K. Liu, William Chu, Hans T. Chung, Gerard Morton, Andrea Deabreu, Melanie Davidson, Ananth Ravi, Joelle Helou, Ling Ho, Liying Zhang, Andrew Loblaw
Summary: The study showed that the novel treatment protocol incorporating MRI dose-painted HDR-BT boost, 5-fraction pelvic RT, and ADT is effective and well-tolerated for intermediate and high-risk prostate cancer patients. The biochemical failure rate was 18.2%, and 71% of patients had PSA < 0.4 ng/ml at 4 years.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Urology & Nephrology
Neal Andruska, Benjamin W. Fischer-Valuck, Michael Waters, Elizabeth Juarez Diaz, Temitope Agabalogun, Eric H. Kim, Zachary L. Smith, Randall J. Brenneman, Hiram A. Gay, Gerald L. Andriole, Jeff M. Michalski, Brian C. Baumann
Summary: This study showed that men with higher LN risk scores and Gleason grade benefited from WPRT. WPRT correlated with improved overall survival in men with Gleason 9 and 10 disease or risk of LN involvement >= 10%.
JOURNAL OF UROLOGY
(2022)
Article
Oncology
Vedang Murthy, Priyamvada Maitre, Sadhana Kannan, Gitanjali Panigrahi, Rahul Krishnatry, Ganesh Bakshi, Gagan Prakash, Mahendra Pal, Santosh Menon, Reena Phurailatpam, Smruti Mokal, Dipika Chaurasiya, Palak Popat, Nilesh Sable, Archi Agarwal, Venkatesh Rangarajan, Amit Joshi, Vanita Noronha, Kumar Prabhash, Umesh Mahantshetty
Summary: In high-risk, locally advanced prostate cancer patients, prophylactic pelvic irradiation showed improved biochemical failure-free survival and disease-free survival compared to prostate-only radiotherapy, though overall survival did not appear to differ significantly.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Wei-Hsin Chen, Yu Khun Lee, Hann-Chorng Kuo, Jen-Hung Wang, Yuan-Hong Jiang
Summary: This study examined the outcomes of robot-assisted radical prostatectomy (RaRP) in high-risk and very high-risk prostate cancer patients. The results showed that high-risk/very high-risk patients without adjuvant treatment had worse biochemical recurrence-free survival compared to those with adjuvant treatment. However, the combination of RaRP and adjuvant treatment resulted in comparable biochemical recurrence-free survival for high-risk/very high-risk patients and below high-risk patients. Additionally, high-risk/very high-risk patients had higher rates of stress urinary incontinence at postoperative week 1 and month 1 compared to below high-risk patients, but there was no significant difference in incontinence rates between the two groups from postoperative 3 months to 12 months.
Article
Biochemistry & Molecular Biology
Marcin Miszczyk, Monika Szoltysik, Maja Hasterok, Gregor Goldner, Pawel Rajwa, Agnieszka Namysl-Kaletka, Aleksandra Napieralska, Malgorzata Kraszkiewicz, Malgorzata Stapor-Fudzinska, Bartlomiej Tomasik, Grzegorz Wozniak, Grzegorz Glowacki, Konrad Kaminiow, Matthias Moll, Lukasz Magrowski, Wojciech Majewski
Summary: Localized prostate cancer can be effectively treated with CyberKnife(TM) ultra-hypofractionated radiotherapy. Salvage therapies are feasible for patients with local-regional failure. Age and occurrence of a second malignancy are important factors affecting patients' survival.
Review
Oncology
Laura Burgess, Soumyajit Roy, Scott Morgan, Shawn Malone
Summary: Traditionally, high-risk prostate cancer is treated with a combination of radiotherapy and androgen deprivation therapy. Recent advancements in systemic treatment and radiotherapy have expanded the treatment spectrum for this patient population. Emerging evidence has redefined the role of surgery and identified new systemic therapy options, as well as ushered in a new era in patient selection, risk stratification, and treatment tailoring with the use of advanced imaging modalities and genomic classifiers.
Article
Oncology
Yuichi Hiroshima, Hitoshi Ishikawa, Yuma Iwai, Masaru Wakatsuki, Takanobu Utsumi, Hiroyoshi Suzuki, Koichiro Akakura, Masaoki Harada, Hideyuki Sakurai, Tomohiko Ichikawa, Hiroshi Tsuji
Summary: As the population ages, the choice of treatment options for elderly prostate cancer patients with poor general condition is becoming more difficult. This retrospective study evaluated the clinical outcomes of carbon-ion radiotherapy for elderly high-risk prostate cancer patients and found that it may be a safe and effective treatment.